Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes.
擴大心臟科醫師的角色以改善心血管健康和結果:優先考慮肥胖治療。
Cardiovasc Endocrinol Metab 2023-02-14
Role of Glucagon-Like Peptide-1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity.
GLP-1受體激動劑在達到減重和改善超重和肥胖人群心血管結果中的作用。
J Am Heart Assoc 2023-08-01
Role of glucagon-like peptide-1 receptor agonists in the treatment of obesity, cardiovascular disease, and cerebrovascular disease.
GLP-1 受體激動劑在肥胖、心血管疾病和腦血管疾病治療中的作用。
Pol Arch Intern Med 2024-04-29
Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions.
肥胖症的新興藥物及其對心臟疾病患者的潛在作用:值得一試嗎?
Curr Cardiol Rep 2024-05-22
Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities.
肥胖常見的心臟代謝併發症在年輕至老年人中的脂肪細胞中心起源:病理生理學和新的治療機會。
Front Med (Lausanne) 2024-04-26
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.
肥胖中 GLP-1 生理學及基於促胰島素的藥物在慢性體重管理中的發展。
Nat Metab 2024-08-19